Neural Regeneration Research, 2014 · DOI: 10.4103/1673-5374.130087 · Published: March 1, 2014
The discovery that somatic mammalian cells can be epigenetically reprogrammed to induced pluripotent stem cells (iPSCs) through the exogenous expression of the Oct4, Sox2, Klf4 and c-Myc (OSKM) has demonstrated a new way for cell-replacement therapy in regenerative medicine. Stem cells have the remarkable potential to develop into many different cell types, essentially without limit to replenish other cells as long as the person or animal is still alive. Just last week, two papers published in Nature, describing a surprisingly simple method to turn mature cells into embryonic-like stem cells by culturing cells in a low pH medium.
iPSCs offer a new avenue for cell-replacement therapy in regenerative medicine.
Cell reprogramming technologies, particularly iPSCs, provide a way to derive stem cells without the ethical concerns associated with embryonic stem cells.
The STAP method, if replicated, could open a new era in stem cell biology and research in tumorigenesis.